Hisamitsu Pharmaceutical Co Inc
TSE:4530

Watchlist Manager
Hisamitsu Pharmaceutical Co Inc Logo
Hisamitsu Pharmaceutical Co Inc
TSE:4530
Watchlist
Price: 4 080 JPY -0.49% Market Closed
Market Cap: 317.1B JPY
Have any thoughts about
Hisamitsu Pharmaceutical Co Inc?
Write Note

Net Margin
Hisamitsu Pharmaceutical Co Inc

9.8%
Current
9%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.8%
=
Net Income
14.7B
/
Revenue
150.2B

Net Margin Across Competitors

Country JP
Market Cap 299.2B JPY
Net Margin
10%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 749.1B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 348B USD
Net Margin
17%
Country US
Market Cap 251.1B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 150.1B USD
Net Margin
7%
No Stocks Found

Hisamitsu Pharmaceutical Co Inc
Glance View

Market Cap
299.2B JPY
Industry
Pharmaceuticals

In the bustling landscape of Japanese pharmaceutical companies, Hisamitsu Pharmaceutical Co., Inc. stands out with its pioneering spirit and deep-rooted dedication to health and wellness. Founded in 1847, the company has evolved over a century and a half, transitioning from a modest establishment selling herbal medicines to a globally recognized manufacturer of pain-relief products. At the core of Hisamitsu's operations is its flagship product, the transdermal patch, featuring the SALONPAS brand as its crown jewel. This innovative delivery system allows active medicinal ingredients to penetrate the skin, addressing pain at its source effectively and efficiently. As global demand for non-invasive pain relief grows, Hisamitsu leverages its expertise in transdermal technology, continuously innovating and expanding its product line to cater to diverse consumer needs. Hisamitsu's success hinges on a solid blend of cutting-edge research, consistent quality, and strategic marketing prowess. By investing heavily in R&D, the company not only enhances its existing product offerings but also explores new therapeutic areas, ensuring a pipeline poised for future growth. Besides Japan, Hisamitsu's market presence extends across the Americas, Europe, and Asia, with international sales contributing significantly to its revenue stream. The company is adept at navigating intricate regulatory landscapes and varying consumer preferences to establish its footprint globally. This strategic expansion, coupled with a relentless commitment to quality, enables Hisamitsu to sustain its profitability while fulfilling its mission of delivering comfort and improved quality of life to people around the world.

Intrinsic Value
4 348.76 JPY
Undervaluation 6%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.8%
=
Net Income
14.7B
/
Revenue
150.2B
What is the Net Margin of Hisamitsu Pharmaceutical Co Inc?

Based on Hisamitsu Pharmaceutical Co Inc's most recent financial statements, the company has Net Margin of 9.8%.